The latest result of an ongoing large randomized controlled trial (NCT02684006) proved that, compared with sunitinib alone, patients with advanced ccRCC receiving avelumab, a new kind of PD-L1 inhibitor, combined with axitinib had a significantly longer progression-free survival time (40, 41). Here, CD274 is linked to nonpapillary renal cell carcinoma.